Barut delivered a speech at the summit’s special session on “Managerial Perception of the Future” and drew attention to the fact that openness to change, adaptation, and foresight would stand out among the most crucial managerial factors in shaping the future. To continue its 10-year leadership position in the industry, Abdi İbrahim would move forward with individuals swayed by such a perception, he added.

Barut explained the importance of these factors: “Within the framework of the 21st century, adaptation means easy adjustment to changes brought about by technology. We see that one third of the Fortune 500 companies have disappeared in the last 13 years and that the average lifespan of European companies in Germany and France has diminished from 45 to 18 years and 13 to 9 years, respectively. A decreased managerial lifespan hints that we should always be on guard, and, within in this context, I am rightfully proud that we at Abdi Ibrahim will be celebrating our 100th anniversary in two years.”

Drawing from examples in his own life, Barut encouraged participants by pointing out that we should be driven, not by worry but by courage: “It is hardly possible to figure out at this moment how the future will be shaped. But what is possible to discern is how we commit our resources to realize our dreams, and, that making choices compatible with our intentions and goals is related to being courageous and having confidence in our instincts.”

Participating with its own booths for the first time in the International Medical Industry Fair and Conference CphI Worldwide 2009 organized in Madrid, Spain between 13-15 October; Abdi İbrahim attracted far more attention than most of the international companies attending the fair, both with its groundbreaking approaches to R & D and its product portfolios prepared in international standards.

Creating a difference with its corporate visuals and stand, Abdi İbrahim is ready to increase its effectiveness in the medical market.

Abdi İbrahim; The new drug Zydena and its compound Udenafil will be well received in the field of erectile dysfunction due to its rapid onset of action, proven efficacy and good tolerability.

Dong-A has started the development for Zydena in year 1997. Following successful trials including US studies, the product has started to be launched in major emerging markets such as Korea and Russia. US and European country launches will follow. The company aims to play a major role in the world’s erectile dysfunction market.

According to the IMS data, the Turkish erecticle disfunction market size is valued of annual 100 million USD.

Korea’s leading biopharmaceutical producer Celltrion has strategic cooperations with various global pharmaceutical companies, with its US FDA approved state of art production facilities and distinguished scientists. With this agreement, Abdi Ibrahim took an initiative that will bring a tremendous impression across the oncology market in Turkey.

According to the IMS data, Turkish oncology market valued 700 million USD in 2008 from which monoclonal antibody products have a share of 250 million USD. With this agreement, Abdi Ibrahim will play a leading role in the oncology market with Celltrion’s biosimilar monoclonal antibodies effective in the treatment of different cancer diseases.

Guidelines and regulations have been issued in the recent years in order to support the health care system in Turkey, whereas biosimilars have been in the focus and given great attention.

Abdi Ibrahim, already ranked amongst the top 100 pharmaceutical companies worldwide, will have a strong presence in the oncology market and continue to be the leading company in the sector.

About Monoclonal Antibodies and Biosimilars

Monoclonal antibodies (or mAb) specifically target cells. The main objective is stimulating the patient's immune system to attack the malignant tumor cells and the prevention of tumor growth by blocking specific cell receptors. This specification of mAb provides efficacy and safety

Biosimilars are the biologic products similar to the original biopharmaceuticals .